Aspire BioPharma, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for subl… Read more
Market Cap & Net Worth: Aspire BioPharma, Inc. (ASBP)
Aspire BioPharma, Inc. (NASDAQ:ASBP) has a market capitalization of $3.51 Million ($3.51 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #34848 globally and #11363 in its home market, demonstrating a -42.69% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aspire BioPharma, Inc.'s stock price $0.70 by its total outstanding shares 5024142 (5.02 Million).
Aspire BioPharma, Inc. Market Cap History: 2025 to 2026
Aspire BioPharma, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $662.68K to $3.51 Million (0.00% CAGR).
Aspire BioPharma, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aspire BioPharma, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ASBP by Market Capitalization
Companies near Aspire BioPharma, Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to Aspire BioPharma, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Aspire BioPharma, Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, Aspire BioPharma, Inc.'s market cap moved from $662.68K to $ 3.51 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.51 Million | +430.10% |
| 2025 | $662.68K | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Aspire BioPharma, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.51 Million USD |
| MoneyControl | $3.51 Million USD |
| MarketWatch | $3.51 Million USD |
| marketcap.company | $3.51 Million USD |
| Reuters | $3.51 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.